Analyst Phil Nadeau works at COWEN and is focused on the Healthcare sector with 176 price targets and ratings documented since 2013 spanning on 13 stocks. Analyst's average stock valuation to be materialised ratio is 50.72% with an average time for price targets to be met of 166.77 days.
Most recent stock forecast was given on GILD, Gilead Sciences, Inc at 28-Oct-2022.
Phil Nadeau best performing recommendations are on IMMU.
The best stock recommendation documented was for BIIB (BIOGEN INC) at 11/4/2020. The price target of $275 was fulfilled within 5 days with a profit of $80.63 (22.67%) receiving and performance score of 45.34.
Average potential price target upside